Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIN: Hydroxyurea for Stroke Prevention in Sickle Cell Disease
NCT01801423Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2013
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hydroxyurea in sickle cell anemia (SCA), sponsored by Vanderbilt University Medical Center. Started Apr 2013; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT01801423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01801423.